H.C. Wainwright raised the firm’s price target on Black Diamond Therapeutics (BDTX) to $12 from $11 and keeps a Buy rating on the shares following the Q4 report. The firm expects another clinical update on BDTX-1535 in Q2.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BDTX: